<DOC>
	<DOCNO>NCT00405067</DOCNO>
	<brief_summary>The main objective study evaluate efficacy safety combination therapy BMS-201038 ( AEGR-733 ) plus ezetimibe vs. agent give alone LDL cholesterol lipoproteins 12 week therapy .</brief_summary>
	<brief_title>The Safety &amp; Efficacy Combination BMS-201038 ( AEGR-733 ) &amp; Ezetimibe vs. Monotherapy Moderate Hypercholesterolemia</brief_title>
	<detailed_description>Subjects participate study approximately 14-17 week . This study 2 period : 1 ) 1-2-week screening period 2 visit baseline cholesterol characteristic evaluate determine study eligibility . This period also include 4-week washout patient prior lipid-lowering therapy ; 2 ) 12-week treatment period interim visit week 4 8 . 85 subject randomize one 3 treatment arm equal probability . In treatment arm 1 , subject receive BMS-201038 ( AEGR-733 ) 5 mg plus ezetimibe placebo . In treatment arm 2 , subject receive BMS-201038 ( AEGR-733 ) placebo plus 10 mg ezetimibe . In treatment arm 3 , subject receive BMS-201038 ( AEGR-733 ) 5 mg plus ezetimibe 10 mg. After 4 week treatment , subject arm 1 3 force-titrated BMS-201038 ( AEGR-733 ) 7.5 mg. After another 4 week treatment , subject arm 1 3 force-titrated BMS-201038 ( AEGR-733 ) 10 mg 4 additional week treatment . Subjects arm 2 continue receive BMS-201038 ( AEGR-733 ) match placebo entire 12 week treatment . Subjects randomize ezetimibe 10 mg arm 2 3 ezetimibe placebo arm 1 remain dos entire 12-week treatment period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>1 . Men woman age 18 70 year . 2 . For subject 0 1 risk factor ( cigarette smoking , hypertension ( BP &gt; 140/90 antihypertensive medication ) , low HDL ( &lt; 40mg/dl ) , family history premature CHD ( CHD male first degree relative &lt; 55 year ; CHD female first degree relative &lt; 65 year ) , age ( men &gt; 45 year ; woman &gt; 55 year ) : Baseline mean LDLC must &gt; 160 &lt; 250 mg/dl determine arithmetic mean measure take visit 1 2 . Fasting mean TGs &lt; 400 mg/dl . 3 . For subject 2 risk factor ( cigarette smoking , hypertension ( BP &gt; 140/90 antihypertensive medication ) , low HDL ( &lt; 40mg/dl ) , family history premature CHD ( CHD male first degree relative &lt; 55 year ; CHD female first degree relative &lt; 65 year ) , age ( men &gt; 45 year ; woman &gt; 55 year ) prior stable CHD : Baseline mean LDLC must &gt; 130 &lt; 250 mg/dl determine arithmetic mean measure take visit 1 2 . Fasting mean TGs &lt; 400 mg/dl . 4 . Able understand willing comply study requirement , particularly study drug regimen . 5 . Able understand willing sign Informed Consent Form . 1 . Women pregnant lactate plan become pregnant woman child bear potential successfully use acceptable contraceptive method previous 3 month ( e.g . intrauterine device barrier method plus spermicide ) . 2 . Uncontrolled hypertension define : systolic blood pressure &gt; 180 mmHg , diastolic blood pressure &gt; 95 mmHg 3 . History chronic renal insufficiency ( serum creatinine &gt; 2.5 mg/dL ) 4 . History liver disease transaminases 1.5 X ULN screen 5 . Any major surgical procedure occur less 3 month prior screen visit 6 . Cardiac insufficiency define NYHA classification functional Class IIClass IV 7 . History malignancy ( basal cell squamous cell carcinoma skin remove ) within previous 5 year 8 . Participation investigational drug study within 6 week prior screen visit . 9 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . 10 . Regular alcohol use &gt; 1 drink per day 11 . Regular consumer grapefruit juice , currently take medication know metabolized CYP 3A4 ( cyclosporine , itraconazole , ketoconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor , nefazodone ) 12 . Other lipidlowering medication ( washout permit ) 13 . Acute CVD ( CVD event within previous 6 month ) 14 . Diabetes Mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cholesterol</keyword>
</DOC>